Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2025Magnificent 7Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary Marketplace / Trade Private Companies / Buy and Sell Scorpion Therapeutics Stock
Scorpion Therapeutics

Scorpion Therapeutics Stock

$821.83MM
Series C-2 Valuation, Jul 2024
Register To Buy and Sell Private Company Shares
For more details on financing and valuation of private companies similar to Scorpion Therapeutics before its M&A, register or login today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

Scorpion Therapeutics Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Scorpion Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
07/16/2024 Series C-2 $24.31MM $xx.xx $821.83MM Abingworth, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Fidelity, Frazier Life Sciences, Invus, Lightspeed Venture Partners, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Willett Advisors, Woodline Partners Lp
Price per Share
$xx.xx
Shares Outstanding
9,579,780
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Fidelity, Frazier Life Sciences, Invus, Lightspeed Venture Partners, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Willett Advisors, Woodline Partners Lp
07/16/2024 Series C-1 $125.69MM $xx.xx $821.83MM Abingworth, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Fidelity, Frazier Life Sciences, Invus, Lightspeed Venture Partners, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Willett Advisors, Woodline Partners Lp
Price per Share
$xx.xx
Shares Outstanding
51,950,479
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Fidelity, Frazier Life Sciences, Invus, Lightspeed Venture Partners, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Willett Advisors, Woodline Partners Lp
01/07/2021 Series B $162MM $xx.xx $578.26MM Abingworth & Partners Healthcare Innovation, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Invus, Janus Henderson Investors, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Woodline Partners Lp
Price per Share
$xx.xx
Shares Outstanding
66,957,944
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth & Partners Healthcare Innovation, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Invus, Janus Henderson Investors, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Woodline Partners Lp
10/26/2020 Series A-2 $55.64MM $xx.xx $191.3MM Abingworth & Partners Healthcare Innovation, Atlas Venture, Omega Funds, Vida Ventures
Price per Share
$xx.xx
Shares Outstanding
42,784,910
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth & Partners Healthcare Innovation, Atlas Venture, Omega Funds, Vida Ventures
10/26/2020 Series A-1 $52.84MM $xx.xx $191.3MM Abingworth & Partners Healthcare Innovation, Atlas Venture, Omega Funds, Vida Ventures
Price per Share
$xx.xx
Shares Outstanding
52,837,500
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth & Partners Healthcare Innovation, Atlas Venture, Omega Funds, Vida Ventures
Company Details
Scorpion Therapeutics is an oncology company focused on transforming cancer treatment through an approach that offers precise selectivity and efficacy for oncology patients. Scorpion Therapeutics was founded in 2020 and is headquartered in Boston, MA. The company uses its proprietary technology platform that integrates cancer biology, medicinal chemistry, and data sciences for a holistic approach. The platform aims to allow Scorpion Therapeutics to create highly selective small-molecule compounds that target a broad spectrum of cancer drivers.
Founded
2020
Headquarters
Boston, MA, United States
Post-Money Valuation 3
$821.83MM
Total Funding
$1.02B
LFR Price per Share
$xx.xx
Last Funding Share Class
Series C-2

Scorpion Therapeutics Stock FAQs

To buy and sell Scorpion Therapeutics stock
Can you buy Scorpion Therapeutics stock?
You can no longer buy Scorpion Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
How to buy Scorpion Therapeutics stock?
You can no longer buy Scorpion Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
Can you sell Scorpion Therapeutics stock?
You can no longer sell stock of Scorpion Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
How to sell Scorpion Therapeutics stock?
You can no longer sell stock of Scorpion Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
To learn more about Scorpion Therapeutics stock
Is Scorpion Therapeutics a public company?
Scorpion Therapeutics is now a public company.
What is Scorpion Therapeutics’ stock price?
The stock price of Scorpion Therapeutics is not currently available.
What is Scorpion Therapeutics’ stock ticker symbol?
The ticker symbol of Scorpion Therapeutics is not currently available.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Scorpion Therapeutics Investors Also Invested in These Private Companies

Hillhouse Investment Group
Abingworth & Partners Healthcare Innovation
Citadel Enterprise Americas
Mass General Brigham Ventures

Leadership & Board

Leadership

Liron Bar-Peled Ph.D
Co-Founder
Keith Flaherty MD
Co-Founder
Gaddy Getz Ph.D
Co-Founder
Gary D. Glick Ph.D
Co-Founder
Adam Friedman MD, Ph.D
Chief Executive Officer
Natasja Brooijmans Ph.D
Senior Vice President of Chemical Data Science
Mark Chao MD, Ph.D
Chief Medical Officer
Andrew Fedder
General Counsel
Angel Guzman-Perez Ph.D
Executive Vice President, Head of Chemistry
Erica L. Jackson Ph.D
Chief Discovery Officer
Valerie Jaiswal
Executive Vice President, Finance
Gregory V. Kryukov Ph.D
Vice President of Data Science
Brent Martin Ph.D
Vice President, Head of Chemical Biology
Brian Piper
Chief Financial Officer
Darrin Stuart Ph.D
Chief Scientific Officer
Amanda Valentino
Chief People Officer

Board

Shelley Chu MD, Ph.D
Lightspeed Venture Partners
Jean-François Formela MD
Atlas Venture
Arjun Goyal MD
Vida Ventures
Oleg Nodelman
EcoR1 Capital
Otello Stampacchia Ph.D
Omega Funds

Scorpion Therapeutics News and Media Highlights

Scorpion Therapeutics Raises $150M in Series C Financing

In a series C funding round led by Frazier Life Sciences and Lightspeed Venture Partners, Scorpion Therapeutics raised $150 million.
Browse Insights
Explore Private Companies in the BioTech & Pharma Sector
Sector: Healthcare
Subsector: BioTech & Pharma
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
Affinia TherapeuticsAffinia Therapeutics----$xx.xxSeries B$365.7MM$xx.xx$110MM
Altos LabsAltos Labs----$xx.xxSeries C$6.33B$xx.xx$1.5B
Colossal BiosciencesColossal Biosciences----$xx.xxSeries C$10.2B$xx.xx$200MM
EgenesisEgenesis----$xx.xxSeries D$332.59MM$xx.xx$90.96MM
Eikon TherapeuticsEikon Therapeutics----$xx.xxSeries D$1.45B$xx.xx$400MM
Isomorphic LabsIsomorphic Labs----$xx.xx--------
Kailera TherapeuticsKailera Therapeutics----$xx.xxSeries A-2 NV$580.71MM$xx.xx$7.09MM
LoyalLoyal----$xx.xxSeries B-5$428.44MM$xx.xx$17.49MM
Mammoth BiosciencesMammoth Biosciences----$xx.xxSeries D-2$1.35B$xx.xx$107.74MM
OriginOrigin----$xx.xx--------

Updated on: Mar 13, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.